KML-29

KML-29 is a highly selective and potent inhibitor of monoacylglycerol lipase (MAGL), an enzyme principally responsible for the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG) into arachidonic acid and glycerol. By inhibiting MAGL, KML-29 increases brain 2-AG levels while reducing arachidonic acid concentrations. This results in antinociceptive (pain-relieving), anti-inflammatory, and neuroprotective effects in preclinical models. Unlike direct cannabinoid receptor agonists, KML-29 does not elicit cannabinoid-like psychoactive side effects. It has been studied in animal models for its neuroprotective effects following ischemic injury, its protective effects against kidney ischemia–reperfusion injury, and its analgesic effects in models of inflammatory and neuropathic pain[1][2][3][4][5][7][9].

Other names

4-[Bis(1,3-benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ester